<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_Duesseldorf skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:Duesseldorf</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><P><TITLE>Home</TITLE></P><DIV class="content"><DIV class="nav"><TABLE style="margin: 0; border: none; width: 100%;"><TBODY><TR style="border:none;"><TD style="border:none;"><UL><LI><A style="color: white;" href="https://2016.igem.org/Team:Duesseldorf">Home</A></LI><LI class="dropdown"><A href="#">Project</A></LI><LI><A href="https://2016.igem.org/Team:Duesseldorf/Description">Description</A></LI><LI><A href="https://2016.igem.org/Team:Duesseldorf/Proof">Results</A></LI><LI><A href="https://2016.igem.org/Team:Duesseldorf/Demonstrate">Demonstrate</A></LI><LI><A href="https://2016.igem.org/Team:Duesseldorf/Future_Applications">Future Applications</A></LI></UL><LI><A href="https://2016.igem.org/Team:Duesseldorf/Collaborations">Collaborations</A></LI><LI class="dropdown"><A href="#">Outreach</A></LI><LI><A href="https://2016.igem.org/Team:Duesseldorf/Outreach">Outreach</A></LI><LI><A href="https://2016.igem.org/Team:Duesseldorf/Outreach#HP">Education</A></LI><LI><A href="https://2016.igem.org/Team:Duesseldorf/Outreach#IHP">Integrated Practices</A></LI><LI><A href="https://2016.igem.org/Team:Duesseldorf/Hardware">Hardware</A></LI><LI><A href="https://2016.igem.org/Team:Duesseldorf/Attributions">Attributions</A></LI><LI><A href="https://2016.igem.org/Team:Duesseldorf/Safety">Safety</A></LI><LI><A href="https://2016.igem.org/Team:Duesseldorf/Team">Team</A></LI><LI><A href="https://2016.igem.org/Team:Duesseldorf/Parts">Parts</A></LI><LI><A href="https://2016.igem.org/Team:Duesseldorf/Experiments">Experiments</A></LI></TD></TR><TR style="border:none;"><TD style="border:none;">
                     Heinrich-Heine University 
                     Universitätsstraße 1 
                     40225 Düsseldorf  
                     Design by Marvin van Aalst </TD></TR></TBODY></TABLE></DIV><DIV class="page"><DIV class="paper"><DIV id="Navigation" class="navigation"><UL class="topnav"><LI><A style="color: black;" href="https://2016.igem.org/Team:Duesseldorf">Home</A></LI><LI><A href="https://2016.igem.org/Team:Duesseldorf/Description">Description</A></LI><LI><A href="https://2016.igem.org/Team:Duesseldorf/Proof">Results</A></LI><LI><A href="https://2016.igem.org/Team:Duesseldorf/Demonstrate">Demonstrate</A></LI><LI><A href="https://2016.igem.org/Team:Duesseldorf/Future_Applications">Future Applications</A></LI><LI><A href="https://2016.igem.org/Team:Duesseldorf/Collaborations">Collaborations</A></LI><LI><A href="https://2016.igem.org/Team:Duesseldorf/Outreach">Outreach</A></LI><LI><A href="https://2016.igem.org/Team:Duesseldorf/Outreach#HP">Education</A></LI><LI><A href="https://2016.igem.org/Team:Duesseldorf/Outreach#IHP">Integrated Practices</A></LI><LI><A href="https://2016.igem.org/Team:Duesseldorf/Hardware">Hardware</A></LI><LI><A href="https://2016.igem.org/Team:Duesseldorf/Attributions">Attributions</A></LI><LI><A href="https://2016.igem.org/Team:Duesseldorf/Safety">Safety</A></LI><LI><A href="https://2016.igem.org/Team:Duesseldorf/Team">Team</A></LI><LI><A href="https://2016.igem.org/Team:Duesseldorf/Parts">Parts</A></LI><LI><A href="https://2016.igem.org/Team:Duesseldorf/Experiments">Experiments</A></LI></UL></DIV><DIV class="article"><H2>Imagine you turn the switch on and the cancer is gone…</H2><P>
Cancer is the second most common cause of death killing about 8.2 million people annually, which equals the total population of New York City. 
The global increase of cancer cases and the <A href="https://2016.igem.org/Team:Duesseldorf/Therapies">lack of highly specific therapies </A>for various types of cancer states a clear message:
New approaches have to be found, which allow a level of precision in cancer treatment that has been long-awaited.
</P><P>
Our approach aims at achieving high spatiotemporal control of <A href="https://2016.igem.org/Team:Duesseldorf/Apoptosis">apoptosis</A> in tumor cells by applying an optogenetic double-killswitch. This <A href="https://2016.igem.org/Team:Duesseldorf/Description">system</A> combines clean removal of cancer cells through apoptosis with the accuracy of light-controlled optogenetics. We utilize two optogenetic proteins, to create the desperately needed holy grail of cancer therapy.
This is the goal of OPTOPTOSIS. 
  </P><H2 id="Medal_Criteria"><A href="https://2016.igem.org/Team:Duesseldorf/Medal_Criteria">Our Achievements</A></H2><DIV class="w3-container" style="margin-bottom:50px;margin-top: 20px;"><DIV id="Bronze" class="w3-container requirement" style="padding-top: 10px;"><H2>Bronze</H2><H4>Register And Attend</H4><UL><LI>Our team was successfully registered and had the greatest summer ever</LI></UL><H4><A href="https://2016.igem.org/Team:Duesseldorf/Attributions">Attribution</A></H4><UL><LI>We created our own Wiki with clear <A href="https://2016.igem.org/Team:Duesseldorf/Attributions">attribution</A> of each aspect of our project</LI></UL><H4>Deliverables </H4><UL><LI>The judging form and <A href="https://2016.igem.org/Team:Duesseldorf/Safety">safety form</A> was completed with great care</LI><LI>We are very excited to present our poster and project talk at the Giant Jamboree</LI><LI>We attributed and acknowledged all of the work done for our project on our Wiki page</LI><LI>We documented and created Part pages for our Parts and submitted the DNA samples of our new Parts to the Registry</LI></UL><H4><A href="https://2016.igem.org/Team:Duesseldorf/Parts">Part/Contribution</A></H4><UL><LI>We are proud of our new standard Biobrick Part and submitted <A href="https://2016.igem.org/Team:Duesseldorf/Parts">BBa_K1936000</A> to the iGEM Registry</LI></UL></DIV><DIV id="Silver" class="w3-container requirement" style="padding-top: 10px;"><H2>Silver</H2><H4><A href="https://2016.igem.org/Team:Duesseldorf/Collaborations">Collaboration </A></H4><UL><LI>We had great <A href="https://2016.igem.org/Team:Duesseldorf/Collaborations">collaborations</A> with other teams and are really happy about our common success  </LI></UL><H4><A href="https://2016.igem.org/Team:Duesseldorf/Parts">Validated Part / Validated Contribution</A></H4><UL><LI>We characterized <A href="https://2016.igem.org/Team:Duesseldorf/Parts">BBa_K1936001</A></LI><LI>This part was submitted to the iGEM registry and is experimentally validated</LI></UL><H4><A href="https://2016.igem.org/Team:Duesseldorf/Outreach#HP">Human Practices</A></H4><UL><LI>Of course, we shared our project and knowledge with the public and talked about the <A href="https://2016.igem.org/Team:Duesseldorf/Ethik">ethical aspects</A>. We had a lot of fun at our different human practice activities.</LI></UL></DIV><DIV id="Gold" class="w3-container requirement" style="padding-top: 10px;"><H2>Gold</H2><H4><A href="https://2016.igem.org/Team:Duesseldorf/Outreach#IHP">Integrated Human Practices</A></H4><UL><LI>Additionally to our <A href="https://2016.igem.org/Team:Duesseldorf/Outreach#HP">Human Practice</A> work we visited the <A href="https://2016.igem.org/Team:Duesseldorf/Outreach#BfArM">BfArM (the german equivalent of the FDA) and telephoned with the Paul Ehrlich Institute</A>, which is responsible for admission of genetherapeutics, to consult professional critics concerning future applications of our project </LI></UL><H4><A href="https://2016.igem.org/Team:Duesseldorf/Proof">Proof of concept</A></H4><UL><LI>We are really happy that we are able to show a functional proof of concept of our project with one of our newly created BioBricks</LI></UL><H4><A href="https://2016.igem.org/Team:Duesseldorf/Demonstrate">Demonstrate your work</A></H4><UL><LI>We were able to show our functional proof of concept under real world conditions with experiments in human cancer cell culture </LI></UL></DIV><DIV id="Special" class="w3-container requirement" style="padding-top: 10px;"><H2>Special</H2><H4>Special Prices</H4><P>
We have done some really good work so we applied for these Special Prices:
</P><UL><LI><A href="https://2016.igem.org/Team:Duesseldorf/Best_Part">Best New Basic Part</A></LI><LI><A href="https://2016.igem.org/Team:Duesseldorf/Outreach#IHP">Best Integrated Human Practice</A></LI><LI><A href="https://2016.igem.org/Team:Duesseldorf/Hardware">Best Hardware Project</A></LI><LI><A href="https://2016.igem.org/Team:Duesseldorf/Outreach#HP">Best Education and Public Engagement</A></LI></UL></DIV></DIV><DIV style="border:5px solid #0C9476;border-radius:25px;padding:10px;"><H2><A href="https://2016.igem.org/Team:Duesseldorf/Proof">Results</A> and engineered constructs of OPTOPTOSIS</H2><P>Our <A href="https://2016.igem.org/Team:Duesseldorf/Proof#">red switch</A> operates as desired
</P><UL><LI>we were able to show that our apoptosis protein is expressed</LI><LI>our testing cells are still alive</LI></UL><P>Our <A href="https://2016.igem.org/Team:Duesseldorf/Proof#">blue switch</A> operates as desired when constitutively expressed
</P><UL><LI>we were able to show that our construct is expressed</LI><LI>we assume that our construct binds to the outer mitochondrial membrane but are still testing it</LI></UL><P>The double transfection of our <A href="https://2016.igem.org/Team:Duesseldorf/Proof#">two constructs</A> worked as desired
</P><UL><LI>we were able to detect gene expression of both constructs in transfected cells</LI><LI>we were able to determine the expression of the red- switch</LI><LI>we have seen indications of induced apoptosis but will further validate it
</LI></UL></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>